Patient demographics (n = 27)
| Characteristic . | Patients . |
|---|---|
| Median age, y (range) | 55 (22-72) |
| Male sex, n (%) | 14 (52) |
| Diagnosis, n (%) | |
| Acute leukemia/MDS | 20 (74) |
| Lymphoma | 5 (18) |
| CML/MM | 2 (3) |
| MA conditioning, n (%) | |
| TBI-based | 4 (15) |
| Chemotherapy-based | 7 (26) |
| RI conditioning, n (%) | |
| TBI-based | 4 (15) |
| Chemotherapy-based | 12 (44) |
| Donor, n (%) | |
| MRD | 4 (15) |
| MUD/MMUD∗ | 13/6 (70) |
| Haploidentical | 4 (15) |
| HLA match, n (%) | |
| 8/8 | 17 (63) |
| 7/8 | 2 (7) |
| <7/8 | 8 (30) |
| Stem cell source, n (%) | |
| BM | 4 (15) |
| PBSC | 19 (70) |
| Cord blood | 4 (15) |
| GVHD prophylaxis, n (%) | |
| CNI ± MTX ± sirolimus | 14 (52) |
| CNI/MMF | 5 (18.5) |
| PTCy/Tacrolimus ± MMF | 8 (29.5) |
| LGI GVHD stage, n (%) | |
| 1 | 9 (33) |
| 2 | 4 (15) |
| 3-4 | 14 (52) |
| Characteristic . | Patients . |
|---|---|
| Median age, y (range) | 55 (22-72) |
| Male sex, n (%) | 14 (52) |
| Diagnosis, n (%) | |
| Acute leukemia/MDS | 20 (74) |
| Lymphoma | 5 (18) |
| CML/MM | 2 (3) |
| MA conditioning, n (%) | |
| TBI-based | 4 (15) |
| Chemotherapy-based | 7 (26) |
| RI conditioning, n (%) | |
| TBI-based | 4 (15) |
| Chemotherapy-based | 12 (44) |
| Donor, n (%) | |
| MRD | 4 (15) |
| MUD/MMUD∗ | 13/6 (70) |
| Haploidentical | 4 (15) |
| HLA match, n (%) | |
| 8/8 | 17 (63) |
| 7/8 | 2 (7) |
| <7/8 | 8 (30) |
| Stem cell source, n (%) | |
| BM | 4 (15) |
| PBSC | 19 (70) |
| Cord blood | 4 (15) |
| GVHD prophylaxis, n (%) | |
| CNI ± MTX ± sirolimus | 14 (52) |
| CNI/MMF | 5 (18.5) |
| PTCy/Tacrolimus ± MMF | 8 (29.5) |
| LGI GVHD stage, n (%) | |
| 1 | 9 (33) |
| 2 | 4 (15) |
| 3-4 | 14 (52) |
BM, bone marrow; CML, chronic myeloid leukemia; CNI, calcineurin inhibitor; LGI, lower gastrointestinal; MA, myeloablative; MDS, myelodysplastic syndrome; MM, multiple myeloma; MMF, mycophenolate mofetil; MMUD, mismatched-unrelated donor; MRD, matched-related donor; MTX, methotrexate; MUD, matched-unrelated donor; PBSC, peripheral blood stem cell; PTCy, post-transplant cyclophosphamide; RI, reduced intensity; TBI, total body irradiation.
Includes 4 patients who received cord blood grafts.